Dr. John Flannery is a Professor of Vision Science and Neuroscience at the University of California, Berkeley. His research program is focused on understanding the genetic and biochemical underpinnings of inherited retinal degenerations and designing genetic therapies for these blinding conditions. The expertise of his laboratory group is directed toward developing viral vectors for gene therapy and gene transfer to retinal neurons, epithelia, and glia. Based on technology from the laboratories of Dr. Ehud Isacoff and John G. Flannery of UC Berkeley, and technology directed at enhanced ocular gene therapy delivery arising jointly between UC Berkeley and the School of Veterinary Medicine at the University of Pennsylvania, Vedere Bio was formed in the Atlas Venture incubator in 2020 and has since been acquired by Novartis and spun out into Vedere Bio II. John received his Ph.D. in Neuroscience from University of California, Santa Barbara in 1982, then was a postdoctoral fellow at the Jules Stein Eye Institute in the UCLA School of Medicine.